Literature DB >> 20038722

INTERESTing biomarker to select IDEAL patients for epidermal growth factor receptor tyrosine kinase inhibitors: yes, for EGFR mutation analysis, others, I PASS.

Ramaswamy Govindan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20038722     DOI： 10.1200/JCO.2009.25.1637

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  5 in total

1.  Imaging: Mass spectrometry in HNSCC--a peek at response prediction?

Authors:  Mei-Kim Ang; D Neil Hayes
Journal:  Nat Rev Clin Oncol       Date:  2010-04       Impact factor: 66.675

2.  Survival and death signals can predict tumor response to therapy after oncogene inactivation.

Authors:  Phuoc T Tran; Pavan K Bendapudi; H Jill Lin; Peter Choi; Shan Koh; Joy Chen; George Horng; Nicholas P Hughes; Lawrence H Schwartz; Vincent A Miller; Toshiyuki Kawashima; Toshio Kitamura; David Paik; Dean W Felsher
Journal:  Sci Transl Med       Date:  2011-10-05       Impact factor: 17.956

Review 3.  Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.

Authors:  E Bria; M Milella; F Cuppone; S Novello; A Ceribelli; V Vaccaro; I Sperduti; A Gelibter; G V Scagliotti; F Cognetti; D Giannarelli
Journal:  Ann Oncol       Date:  2011-02-16       Impact factor: 32.976

4.  Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC.

Authors:  Sandrine Dufort; Marie-Jeanne Richard; Sylvie Lantuejoul; Florence de Fraipont
Journal:  J Exp Clin Cancer Res       Date:  2011-05-16

5.  An Evidence-Based Approach to the Use of Predictive Biomarkers in the Treatment of Non- Small Cell Lung Cancer (NSCLC).

Authors:  Cindy Quinton; Peter M Ellis
Journal:  Cancers (Basel)       Date:  2011-09-13       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.